Bicycle Therapeutics PLC
BCYC5.660USD
+0.350+6.59%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
282.26MMarket Cap
LossP/E TTM
More Details of Bicycle Therapeutics PLC Company
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics PLC Info
Ticker SymbolBCYC
Company nameBicycle Therapeutics PLC
IPO dateMay 23, 2019
CEOLee (Kevin)
Number of employees305
Security typeDepository Receipt
Fiscal year-endMay 23
AddressBlocks A & B, Portway Building
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeCB21 6GS
Phone11441223261503
Websitehttps://www.bicycletherapeutics.com/
Ticker SymbolBCYC
IPO dateMay 23, 2019
CEOLee (Kevin)
Company Executives of Bicycle Therapeutics PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-84339.00%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+30777.00%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-48502.00%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+6062.00%
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Independent Director
Independent Director
3.03K
+3032.00%
Sir Gregory Winter
Sir Gregory Winter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Dr. Jose Carlos Gutierrez-Ramos, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Alethia R. Young, M.D.
Ms. Alethia R. Young, M.D.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Stephen Sands
Mr. Stephen Sands
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Felix J. Baker, Ph.D.
Mr. Felix J. Baker, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Kevin Lee, Ph.D.
Dr. Kevin Lee, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
275.59K
-84339.00%
Dr. Michael Skynner, Ph.D.
Dr. Michael Skynner, Ph.D.
Chief Technology Officer
Chief Technology Officer
72.92K
+30777.00%
Mr. Alistair Milnes
Mr. Alistair Milnes
Chief Operating Officer
Chief Operating Officer
25.33K
-48502.00%
Ms. Janice Bourque
Ms. Janice Bourque
Non-Executive Independent Director
Non-Executive Independent Director
18.31K
+6062.00%
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Independent Director
Independent Director
3.03K
+3032.00%
Sir Gregory Winter
Sir Gregory Winter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Feb 7
Updated: Sat, Feb 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
21.88%
Forbion Capital Partners
6.91%
Armistice Capital LLC
5.96%
Westfield Capital Management Company, L.P.
5.91%
Invus Public Equities Advisors, LLC
4.03%
Other
55.30%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
21.88%
Forbion Capital Partners
6.91%
Armistice Capital LLC
5.96%
Westfield Capital Management Company, L.P.
5.91%
Invus Public Equities Advisors, LLC
4.03%
Other
55.30%
Shareholder Types
Shareholders
Proportion
Hedge Fund
37.53%
Investment Advisor
16.03%
Investment Advisor/Hedge Fund
14.13%
Venture Capital
7.08%
Research Firm
3.61%
Individual Investor
1.48%
Pension Fund
0.49%
Family Office
0.25%
Other
19.40%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
242
39.22M
114.58%
+31.05K
2025Q3
266
40.06M
126.53%
-4.18M
2025Q2
264
44.22M
123.05%
-338.39K
2025Q1
249
44.93M
127.83%
-16.05M
2024Q4
249
44.97M
130.44%
+273.71K
2024Q3
245
43.83M
123.27%
+876.01K
2024Q2
237
43.44M
106.75%
+5.72M
2024Q1
253
34.16M
113.53%
-14.25M
2023Q4
258
34.56M
124.36%
-3.64M
2023Q3
255
38.68M
90.77%
+8.35M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
10.89M
21.8%
--
--
Sep 30, 2025
Forbion Capital Partners
3.45M
6.91%
--
--
Sep 30, 2025
Armistice Capital LLC
2.98M
5.96%
+178.00K
+6.36%
Sep 30, 2025
Westfield Capital Management Company, L.P.
2.95M
5.91%
+172.05K
+6.19%
Sep 30, 2025
Invus Public Equities Advisors, LLC
2.01M
4.03%
--
--
Sep 30, 2025
Long Focus Capital Management LLC
1.42M
2.84%
+101.40K
+7.70%
Sep 30, 2025
T. Rowe Price Associates, Inc.
1.38M
2.77%
-83.60K
-5.69%
Sep 30, 2025
Candriam Luxembourg S.A.
1.35M
2.7%
+731.00
+0.05%
Nov 30, 2025
Acadian Asset Management LLC
1.31M
2.63%
+616.05K
+88.20%
Sep 30, 2025
Candriam Belgium S.A.
1.17M
2.35%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.63%
Invesco NASDAQ Future Gen 200 ETF
0.59%
Harbor Health Care ETF
0.23%
ALPS Medical Breakthroughs ETF
0.17%
iShares Health Innovation Active ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
SPDR S&P International Small Cap ETF
0.03%
iShares Biotechnology ETF
0.02%
ActivePassive International Equity ETF
0%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.63%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.59%
Harbor Health Care ETF
Proportion0.23%
ALPS Medical Breakthroughs ETF
Proportion0.17%
iShares Health Innovation Active ETF
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
SPDR S&P International Small Cap ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.02%
ActivePassive International Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
